Recently a new osteoporosis treatment has been created for postmenopausal women. Amgen has created Prolia, an injectable drug that is a RANK ligand inhibitor, so it aids bone density to prevent severe osteoporosis. Women who take Prolia have a "twice-yearly 60-mg subcutaneous injection." This treatment has been FDA approved and immensely tested, the results positively demonstrating that it reduces bone fractures.
Some side effects of the drug are back pain, musculoskeletal pain, high cholesterol, urinary bladder infections, hypocalcemia, infections of the skin, dermatitis, rashes, and eczema. Additionally, Prolia may cause "significant suppression of bone turnover and this suppression may contribute to the occurrence of osteonecrosis of the jaw, a severe bone disease that affects the jaw, atypical fractures, and delayed fracture healing."
[Source: http://www.pharmacist.com/AM/Template.cfm?Section=Pharmacy_News&template=/CM/ContentDisplay.cfm&ContentID=23563]
No comments:
Post a Comment